Literature DB >> 9842984

Pharmacokinetics of [125I]-recombinant human interleukin-11: 1. Absorption, distribution and excretion after subcutaneous administration to male rats.

T Uchida1, K Aoyama, K Mori, T Usui, T Watanabe, Y Takariki, N Asahara, M Hirose, T Kimura, M Tateishi, S Higuchi.   

Abstract

Absorption, distribution, metabolism and excretion of [125I]-rhIL-11 (recombinant human interleukin-11) after subcutaneous administration in rats were investigated. After a single administration, the concentration of radioactivity in the tissues was 2-6-fold higher in the liver and kidneys, and slightly higher in the gastrointestinal tract as compared to the plasma concentration. However, since the concentration in the other tissues was lower than the plasma concentration, the transport of rhIL-11 into tissues appeared to be low. Tissue radioactivity rapidly diminished, thus accumulation of rhIL-11 in tissues was thought to be low. Excretion of radioactivity into urine and feces was almost complete 72 h after administration, with 88.5% of the dosed radioactivity being found in urine and 7.9% in feces. When [125I]-rhIL-11 was administered to bile-duct cannulated rats, 44.4% of the dosed radioactivity was excreted into bile up to 48 h after administration. Most radioactivity in bile and urine was found in the TCA supernatant and low molecular weight fraction by HPLC analysis, indicating that rhIL-11 was eliminated from the body by metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842984     DOI: 10.1007/BF03192301

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney.

Authors:  A Takagi; Y Yabe; Y Oka; K Sawai; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

2.  Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.

Authors:  A Takagi; H Masuda; Y Takakura; M Hashida
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

3.  Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.

Authors:  S R Paul; F Bennett; J A Calvetti; K Kelleher; C R Wood; R M O'Hara; A C Leary; B Sibley; S C Clark; D A Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture.

Authors:  Y Yonemura; M Kawakita; T Masuda; K Fujimoto; K Kato; K Takatsuki
Journal:  Exp Hematol       Date:  1992-09       Impact factor: 3.084

5.  Characterization of interleukin-11 receptor and protein tyrosine phosphorylation induced by interleukin-11 in mouse 3T3-L1 cells.

Authors:  T Yin; K Miyazawa; Y C Yang
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

6.  Interleukin-11 enhances human megakaryocytopoiesis in vitro.

Authors:  M Teramura; S Kobayashi; S Hoshino; K Oshimi; H Mizoguchi
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

7.  Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin.

Authors:  J P Leonard; C M Quinto; M K Kozitza; T Y Neben; S J Goldman
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

Review 8.  Interleukin-11: a novel stroma-derived cytokine.

Authors:  I Kawashima; Y Takiguchi
Journal:  Prog Growth Factor Res       Date:  1992

9.  Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice.

Authors:  T Y Neben; J Loebelenz; L Hayes; K McCarthy; J Stoudemire; R Schaub; S J Goldman
Journal:  Blood       Date:  1993-02-15       Impact factor: 22.113

  9 in total
  1 in total

1.  In vivo absorption properties of orally administered recombinant human interleukin-11.

Authors:  C M Tseng; L Albert; R L Peterson; P Bouchard; A J Dorner; J Keith; S P Khor
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.